

Alessandra Zingoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7615232/publications.pdf>

Version: 2024-02-01

63
papers

3,978
citations

136950

32
h-index

123424

61
g-index

65
all docs

65
docs citations

65
times ranked

5337
citing authors

#	ARTICLE	IF	CITATIONS
1	ATM-ATRâ€œdependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. <i>Blood</i> , 2009, 113, 3503-3511.	1.4	384
2	Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis. <i>Blood</i> , 2007, 110, 606-615.	1.4	257
3	Cross-Talk between Activated Human NK Cells and CD4+ T Cells via OX40-OX40 Ligand Interactions. <i>Journal of Immunology</i> , 2004, 173, 3716-3724.	0.8	238
4	Aberrant in Vivo T Helper Type 2 Cell Response and Impaired Eosinophil Recruitment in Cc Chemokine Receptor 8 Knockout Mice. <i>Journal of Experimental Medicine</i> , 2001, 193, 573-584.	8.5	222
5	NKG2D and Its Ligands: â€œOne for All, All for Oneâ€œ. <i>Frontiers in Immunology</i> , 2018, 9, 476.	4.8	165
6	Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity. <i>Journal of General Virology</i> , 2007, 88, 242-250.	2.9	161
7	Interplay of protein corona and immune cells controls blood residency of liposomes. <i>Nature Communications</i> , 2019, 10, 3686.	12.8	160
8	DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NKâ€œT cell interaction. <i>Blood</i> , 2011, 117, 4778-4786.	1.4	118
9	The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells. <i>Frontiers in Immunology</i> , 2014, 4, 508.	4.8	110
10	Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis. <i>Oncotarget</i> , 2017, 6, e1279372.	4.6	100
11	Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance. <i>Frontiers in Immunology</i> , 2017, 8, 1194.	4.8	100
12	Engagement of NKG2D by Cognate Ligand or Antibody Alone Is Insufficient to Mediate Costimulation of Human and Mouse CD8+ T Cells. <i>Journal of Immunology</i> , 2005, 174, 1922-1931.	0.8	96
13	Exosome-delivered microRNAs promote IFN-Î± secretion by human plasmacytoid DCs via TLR7. <i>JCI Insight</i> , 2018, 3, .	5.0	96
14	Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment. <i>Cancer Research</i> , 2015, 75, 4766-4777.	0.9	86
15	Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells. <i>Journal of Immunology</i> , 2015, 195, 736-748.	0.8	85
16	NK cell regulation of T cell-mediated responses. <i>Molecular Immunology</i> , 2005, 42, 451-454.	2.2	83
17	The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma. <i>Oncotarget</i> , 2015, 6, 23609-23630.	1.8	78
18	Human Leukocyte Antigen E Contributes to Protect Tumor Cells from Lysis by Natural Killer Cells. <i>Neoplasia</i> , 2011, 13, 822-IN14.	5.3	73

#	ARTICLE	IF	CITATIONS
19	Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay. <i>Journal of Hematology and Oncology</i> , 2016, 9, 134.	17.0	72
20	Senescent cells: Living or dying is a matter of NK cells. <i>Journal of Leukocyte Biology</i> , 2019, 105, 1275-1283.	3.3	69
21	Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells. <i>Blood</i> , 2009, 113, 2955-2964.	1.4	66
22	Inhibition of Glycogen Synthase Kinase-3 Increases NKG2D Ligand MICA Expression and Sensitivity to NK Cell-Mediated Cytotoxicity in Multiple Myeloma Cells: Role of STAT3. <i>Journal of Immunology</i> , 2013, 190, 6662-6672.	0.8	64
23	NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma. <i>BioMed Research International</i> , 2015, 2015, 1-9.	1.9	61
24	Drug-Induced Senescent Multiple Myeloma Cells Elicit NK Cell Proliferation by Direct or Exosome-Mediated IL15 Trans-Presentation. <i>Cancer Immunology Research</i> , 2018, 6, 860-869.	3.4	59
25	Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation. <i>BMC Cancer</i> , 2015, 15, 17.	2.6	54
26	Natural Killer (NK) Cells from Killers to Regulators: Distinct Features Between Peripheral Blood and Decidual NK Cells. <i>American Journal of Reproductive Immunology</i> , 2007, 58, 280-288.	1.2	53
27	NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses. <i>Frontiers in Immunology</i> , 2012, 3, 408.	4.8	53
28	Src-Dependent Syk Activation Controls CD69-Mediated Signaling and Function on Human NK Cells. <i>Journal of Immunology</i> , 2002, 169, 68-74.	0.8	45
29	Impact of the protein corona on nanomaterial immune response and targeting ability. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1615.	6.1	44
30	High-efficient lentiviral vector-mediated gene transfer into primary human NK cells. <i>Experimental Hematology</i> , 2006, 34, 1344-1352.	0.4	39
31	c-Myb regulates MICA but not ULBP2-induced NKG2D down-regulation in human NK cells. <i>European Journal of Immunology</i> , 2014, 44, 2761-2770.	2.9	35
32	Hepatitis C virus direct-acting antiviral therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties. <i>Liver International</i> , 2018, 38, 1741-1750.	3.9	35
33	When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer. <i>Science Advances</i> , 2022, 8, eabj3286.	10.3	35
34	Cancer Exosomes as Conveyors of Stress-Induced Molecules: New Players in the Modulation of NK Cell Response. <i>International Journal of Molecular Sciences</i> , 2019, 20, 611.	4.1	34
35	MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 926.	4.8	33
36	Recognition of a carbohydrate xenoepitope by human NKR1A (CD161). <i>Xenotransplantation</i> , 2006, 13, 440-446.	2.8	32

#	ARTICLE	IF	CITATIONS
37	NKG2D Ligand Shedding in Response to Stress: Role of ADAM10. <i>Frontiers in Immunology</i> , 2020, 11, 447.	4.8	30
38	p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells. <i>Oncolmmunology</i> , 2017, 6, e1264564.	4.6	29
39	Key Role of the CD56 ^{low} CD16 ^{low} Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells. <i>Cancers</i> , 2018, 10, 473.	3.7	29
40	Tuning the Orchestra: HCMV vs. Innate Immunity. <i>Frontiers in Microbiology</i> , 2020, 11, 661.	3.5	29
41	Distinct Roles for Human Cytomegalovirus Immediate Early Proteins IE1 and IE2 in the Transcriptional Regulation of MICA and PVR/CD155 Expression. <i>Journal of Immunology</i> , 2016, 197, 4066-4078.	0.8	28
42	Translating the anti-myeloma activity of Natural Killer cells into clinical application. <i>Cancer Treatment Reviews</i> , 2018, 70, 255-264.	7.7	28
43	Oposonin-Deficient Nucleoproteic Corona Endows UnPEGylated Liposomes with Stealth Properties <i>in Vivo</i> . <i>ACS Nano</i> , 2022, 16, 2088-2100.	14.6	28
44	Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients. <i>Oncolmmunology</i> , 2015, 4, e990773.	4.6	27
45	Targeting NKG2D and NKp30 Ligands Shedding to Improve NK Cell-Based Immunotherapy. <i>Critical Reviews in Immunology</i> , 2016, 36, 445-460.	0.5	27
46	An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1479-1492.	4.2	22
47	Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12176.	12.2	22
48	Bone Marrow Stromal Cell-Derived IL-8 Upregulates PVR Expression on Multiple Myeloma Cells via NF- κ B Transcription Factor. <i>Cancers</i> , 2020, 12, 440.	3.7	21
49	Post-translational Mechanisms Regulating NK Cell Activating Receptors and Their Ligands in Cancer: Potential Targets for Therapeutic Intervention. <i>Frontiers in Immunology</i> , 2019, 10, 2557.	4.8	20
50	Activation of liver X receptor upregulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms. <i>FASEB Journal</i> , 2019, 33, 9489-9504.	0.5	19
51	Immune complexes exposed on mast cell-derived nanovesicles amplify allergic inflammation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1260-1263.	5.7	18
52	Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 2435.	3.7	15
53	Cancer extracellular vesicles as novel regulators of NK cell response. <i>Cytokine and Growth Factor Reviews</i> , 2020, 51, 19-26.	7.2	13
54	Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition. <i>Cell Death and Disease</i> , 2021, 12, 836.	6.3	13

#	ARTICLE	IF	CITATIONS
55	SAMHD1 phosphorylation and cytoplasmic relocalization after human cytomegalovirus infection limits its antiviral activity. <i>PLoS Pathogens</i> , 2020, 16, e1008855.	4.7	12
56	The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors. <i>Cell Death and Disease</i> , 2019, 10, 324.	6.3	11
57	The Possible Role of Sex As an Important Factor in Development and Administration of Lipid Nanomedicine-Based COVID-19 Vaccine. <i>Molecular Pharmaceutics</i> , 2021, 18, 2448-2453.	4.6	11
58	NK cell effector functions in a ChÅ©diak-Higashi patient undergoing cord blood transplantation: Effects of in vitro treatment with IL-2. <i>Immunology Letters</i> , 2016, 180, 46-53.	2.5	7
59	High expression levels of IP10/CXCL10 are associated with modulation of the natural killer cell compartment in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2493-2496.	1.3	6
60	Cereblon regulates NK cell cytotoxicity and migration via Rac1 activation. <i>European Journal of Immunology</i> , 2021, 51, 2607-2617.	2.9	5
61	Modulation of T Cell-Mediated Immune Responses by Natural Killer Cells. , 2010, , 315-327.		4
62	<i>In vitro</i> and <i>ex vivo</i> nano-enabled immunomodulation by the protein corona. <i>Nanoscale</i> , 2022, 14, 10531-10539.	5.6	3
63	PIGR-enriched circulating vesicles contributes to hepatocellular carcinoma aggressiveness. <i>Journal of Hepatology</i> , 2022, 76, 768-770.	3.7	1